|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||
| Current assets: | |||||||||||||
| Cash and cash equivalents | |||||||||||||
| Accounts receivable | |||||||||||||
| Nonrelated Party | |||||||||||||
| Related Party | |||||||||||||
| Total accounts receivable | |||||||||||||
| Tax credits receivable | |||||||||||||
| Income tax receivable | |||||||||||||
| Deferred offering costs | |||||||||||||
| Prepaid expenses | |||||||||||||
| Total current assets | |||||||||||||
| Property and equipment, net | |||||||||||||
| Financing lease right-of-use asset, net | |||||||||||||
| Operating lease right-of-use asset, net | |||||||||||||
| Intangible assets, net | |||||||||||||
| Deferred patent costs | |||||||||||||
| Deferred issuance costs | |||||||||||||
| Other assets | |||||||||||||
| Total assets | |||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||||
| Current liabilities: | |||||||||||||
| Accounts payable | |||||||||||||
| Income tax payable | |||||||||||||
| Current financing lease liability | |||||||||||||
| Current operating lease liability | |||||||||||||
| Insurance premium financing liability | |||||||||||||
| Accrued expenses | |||||||||||||
| Total current liabilities | |||||||||||||
| Long-term financing lease liability | |||||||||||||
| Long-term operating lease liability | |||||||||||||
| Warrant liability | |||||||||||||
| Total liabilities | |||||||||||||
| Convertible preferred stock | |||||||||||||
| Stockholders' equity | |||||||||||||
| Preferred stock; $0.0001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025; respectively. | |||||||||||||
| Common stock; $0.0001 par value, 750,000,000 and 200,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively, 60,603,742 and 10,740,697 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively. | |||||||||||||
| Additional paid-in capital | |||||||||||||
| Accumulated deficit | |||||||||||||
| Total stockholders' equity | |||||||||||||
| Total liabilities and stockholders' equity | |||||||||||||
Loading...
